Multimodal biomarkers combining liquid biopsy, AI-based imaging, and tumor immune profiling may improve early detection and immunotherapy assessment in hepatocellular carcinoma.
- Open access
Hepatocellular Carcinoma Treatment and Prognosis
Moving in Journal of hepatology, The lancet. Gastroenterology & hepatology, Nature Communications, Nature reviews. Gastroenterology & hepatology, bioRxiv, Blood, Communications Biology and Frontiers in Genetics.
- Moved, week to 23 Oct 2026
- 0
- Papers in 60 days
- 31
Add Hepatocellular Carcinoma Treatment and Prognosis as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest
Rebuilt
Moved this week
Nothing in this topic has moved yet this week.
Latest in Hepatocellular Carcinoma Treatment and Prognosis
Newest first · last 60 days
Immune checkpoint inhibitor-based combinations are now the standard first-line systemic therapy for advanced hepatocellular carcinoma, showing improved survival and response rates.
- Open access
Integrating systemic therapy at earlier stages of liver cancer shows promising but uncertain benefits, with data supporting combination approaches in hepatocellular carcinoma and biliary tract cancers.
- Open access
Advances in liver cancer imaging now enable biological characterization and personalized treatment guidance beyond traditional detection methods.
- Open access
- 1 cites
Primary liver cancer incidence and mortality increased by over 55% globally from 2000 to 2023, reversing earlier declines around 2020.
- Open access
Advances in surgical planning and molecular understanding are expanding the resectability of liver cancers, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
- 1 cites
Blood-based biomarkers show promise for liver cancer but require further validation before widespread clinical use.
Liver cancer surveillance lacks randomized trial evidence, with most positive results being false positives in low-prevalence populations, limiting support beyond hepatology.
- Open access
- 1 cites
AI-driven multimodal models outperform single-modality approaches in predicting recurrence and survival in liver cancer patients.
- Open access
Actin cytoskeletal dynamics are crucial for hepatic myofibroblast activities involved in liver fibrosis.
YAP1 induces hepatocellular carcinoma through DNA demethylation, not canonical driver gene mutations, with widespread demethylation activating oncogenes in mouse models.
- Open access
Pharmacological plasminogen reduction significantly enhances liver regeneration and decreases posthepatectomy liver failure in mice and humans, with tranexamic acid showing clinical promise.
- Open access
Abbreviated MRI protocols and blood-based biomarkers show promise for improving hepatocellular carcinoma surveillance accuracy and patient adherence.
Add Hepatocellular Carcinoma Treatment and Prognosis as an interest in JClub
Browse JClub
Journals this month
- bioRxiv6131
- medRxiv1703
- PNAS447
- Sci Adv354
- JAMA262
- Environ Res230
- BMJ182
- Environ Pollution165
- Nat Commun161
- Science141
- Nature138
- Lancet128
- Cell Rep120
- NEJM119
- mBio107
- Plant Cell Environ107
- Curr Biol106
- J Exp Bot106
Topics moving, week to 23 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Bacteriophages and microbial interactions5
- Gut microbiota and health5
- Genomics and Phylogenetic Studies4
- Cancer Genomics and Diagnostics4
- Cancer Immunotherapy and Biomarkers4
- Alzheimer's disease research and treatments3
- Inflammatory Bowel Disease3
- Influenza Virus Research Studies3